Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS IN BRIEF
December 23, 2002
- Bill on New Drug Organization Clears the Diet
December 23, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 23, 2002
- No Meaningful Progress on Mutual Recognition: MOSS Follow-up Talks
December 23, 2002
- OTC NEWS IN BRIEF
December 23, 2002
- Sanofi-Synthelabo to Further Boost Investment in Japan in 2003
December 16, 2002
- Sanus, Honma Toho: Return to the Black with Improved Profitability
December 16, 2002
- Bayer Biological Products to License IVIG Production Technology to JRC
December 16, 2002
- Tax Deduction from Total Clinical Research Cost to Be Allowed
December 16, 2002
- Novartis Aims For 10% Statin Market Share for Lochol
December 16, 2002
- Ando Chemical Works: Sales Post 6% Increase
December 16, 2002
- REGULATORY NEWS IN BRIEF
December 16, 2002
- Kissei Licenses KUC-7483 to Boehringer Ingelheim
December 16, 2002
- Hokuyaku: Profits Jump with Slight Increase in Sales
December 16, 2002
- Allow For-profit Corporations to Operate Medical Facilities: JPMA Forum
December 16, 2002
- Asahi Kasei Aims For \200 Bil. Sales for Health Care Business
December 16, 2002
- Proposal of Designation of Bio-derived Products at the Final Stage
December 16, 2002
- Toyama Accelerates Development of T-3811
December 16, 2002
- Nihon Rinsho Yakuri Kenkyusho to Tie Up with Americas Doctor
December 16, 2002
- Report Compiled on Definition of SMOs: Korosho Panel
December 16, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…